Clinical Trial: Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07225361) titled 'Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis' on Oct. 29.

Brief Summary: In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims:

1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of ~12 months.

2. study the pre- and post-treatment change in plasma neurofilament light chain, tested at baseline pre-Ublituximab treatment, and q24 weeks for 96 weeks post Ublituximab treatment initiation.

Study Start Date: Nov. 01

Study Type: INTERVENTIONAL

Condi...